share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Goodman Tony

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股變動聲明
美股sec公告 ·  03/27 18:10
Moomoo AI 已提取核心訊息
Tony Goodman, the Chief Operating Officer of Adial Pharmaceuticals, Inc. (ADIL), was reported to have engaged in a transaction involving the company's stock on March 25, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of the shares, were not disclosed in the announcement. The number of shares held by Goodman after the transaction was also not provided. This information is crucial for investors to understand the insider activity within Adial Pharmaceuticals and may influence their investment decisions.
Tony Goodman, the Chief Operating Officer of Adial Pharmaceuticals, Inc. (ADIL), was reported to have engaged in a transaction involving the company's stock on March 25, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of the shares, were not disclosed in the announcement. The number of shares held by Goodman after the transaction was also not provided. This information is crucial for investors to understand the insider activity within Adial Pharmaceuticals and may influence their investment decisions.
據報道，阿迪爾製藥公司（ADIL）首席運營官託尼·古德曼於2024年3月25日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易後古德曼持有的股票數量。這些信息對於投資者了解Adial Pharmicals內部活動至關重要，並可能影響他們的投資決策。
據報道，阿迪爾製藥公司（ADIL）首席運營官託尼·古德曼於2024年3月25日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易後古德曼持有的股票數量。這些信息對於投資者了解Adial Pharmicals內部活動至關重要，並可能影響他們的投資決策。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息